The relationship between gene polymorphism and CRP level in a Chinese Han population
Ming Yan1, Lei Zhao, Fang Zheng
1Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, Hubei 430071, PR China.
Biochemical Genetics
|January 16, 2007
Summary
The C-reactive protein (CRP) gene +1444C/T polymorphism influences basal CRP levels in healthy individuals, but does not significantly alter coronary heart disease risk in the studied population.
Area of Science:
- Genetics
- Cardiovascular Disease Epidemiology
Background:
- C-reactive protein (CRP) is a key inflammatory marker associated with cardiovascular disease risk.
- Genetic variations in the CRP gene may influence CRP levels and disease susceptibility.
Purpose of the Study:
- To investigate the association between the CRP gene +1444C/T polymorphism and CRP levels.
- To examine the relationship between this polymorphism and the risk of coronary heart disease (CHD).
Main Methods:
- Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to genotype the +1444C/T polymorphism.
- CRP and lipid levels were measured in 128 CHD patients and 119 healthy controls.
- Genotype and allele frequencies were compared between groups.
Main Results:
- No significant differences in genotype or allele frequencies of the +1444C/T polymorphism were observed between CHD patients and controls.
- The CRP gene +1444C/T polymorphism showed significant differences in genotype and allele distribution compared to Caucasian populations in the Chinese Han population.
- In healthy controls, individuals with the CC genotype had significantly higher CRP concentrations than those with the CT genotype.
Conclusions:
- The CRP gene +1444C/T variant appears to influence basal CRP levels in normal individuals.
- This polymorphism did not demonstrate a significant association with coronary heart disease risk in this cohort.
- Genotype-specific risk thresholds for CRP levels may be warranted in the future.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...